Showing 3091-3100 of 10494 results for "".
Optimizing Wound Healing for Cosmetic and Medical Dermatologic Procedures
https://practicaldermatology.com/topics/practice-management/optimizing-wound-healing-for-cosmetic-and-medical-dermatologic-procedures/20522/Among the options for wound management is hypochlorous acid, a broad-action antimicrobial and anti-inflammatory agent.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-25/23543/The Complex and Heterogeneous Pathophysiology of Atopic Dermatitis: Many Facets of Disease
https://practicaldermatology.com/topics/atopic-dermatitis/the-complex-and-heterogeneous-pathophysiology-of-atopic-dermatitis-many-facets-of-disease/23912/Are We What We Eat?
https://practicaldermatology.com/columns/clinical-focus-1/are-we-what-we-eat/23507/Understanding adverse food reactions and their role in atopic dermatitis.Approval for Evolus; Remembering Vic Narurkar, MD
https://practicaldermatology.com/topics/practice-management/dermwiretv-approval-for-evolus-remembering-vic-narurkar-md/19553/The FDA has approved Jeuveau, the lead product from Evolus, Inc. David Moatazedi, President and CEO of Evolus, and Michael Jafar, Chief Marketing Officer at Evolus, comment on market potential for the new product.Twenty-eight percent of physicians say the prior authorization process required by healAltreno's Approval, Psoriasis Insights
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-altreno-s-approval-psoriasis-insights--nxhineya/18236/Ortho Dermatologics' Altreno lotion is now approved for the topical treatment of acne vulgaris in patients ages 9 and up. Altreno, containing tretinoin 0.05%, will be available during the fourth quarter of this year. The FDA has accepted Ortho Dermatologics' resubmitted New Drug Application for DuobDEI in Dermatology
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/dei-in-dermatology/20143/Dermatology remains one of the least diverse medical specialties, says Jeanine Downie, MD. There have been small steps forward to improve diversity, equity, inclusion, and accessibility in recent years, such as the DREAM initiative from Allergan Aesthetics and skinbetter science. But there is stillDermWireTV: Candela + Merz Aesthetics Partnership, COVID-19 Vaccines & Fillers, Almirall's Klisyri, MetSyn & PsO
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-candela-merz-aesthetics-partnership-covid-19-vaccines-and-fillers-almiralls-klisyri-metsyn-and-pso/19893/Klisyri® (tirbanibulin) ointment 1% from Almirall will be available for treatment of AKs by the end of this quarter; Ayman Grada, MD discusses. Are patients who have received dermal filler injections at risk for developing reactions to the COVID-19 vaccine? Joel L. Cohen, MD and Doris Day, MD weighDermWireTV: Zilxi Launch, Eczema Awareness, Uninsurance Rates
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-zilxi-launch-eczema-awareness-uninsurance-rates/19863/For eczema awareness month, the National Eczema Association (NEA) is offering virtual educational programs, community engagement activities, and additional free resources. Georgia, Oklahoma, and Texas have the highest rates of uninsurance. Zilxi minocycline topical foam launches as new data fromDermWireTV: Enbrel/AD Link, LGBTQ Health and Dermatology
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-enbrelad-link-lgbtq-health-and-dermatology/19624/Signals in accumulated data for Enbrel seem to suggest that etanercept may have a protective effect against Alzheimer’s disease, the Washington Post reported earlier this month. The AAD position statement on Sexual and Gender Minority Health in Dermatology says that, “Dermatologists can and should c